PLoS ONE (Jan 2020)

Analysis of biliary MICRObiota in hepatoBILIOpancreatic diseases compared to healthy people [MICROBILIO]: Study protocol.

  • Fernanda Sayuri do Nascimento,
  • Milena Oliveira Suzuki,
  • João Victor Taba,
  • Vitoria Carneiro de Mattos,
  • Leonardo Zumerkorn Pipek,
  • Eugênia Machado Carneiro D'Albuquerque,
  • Leandro Iuamoto,
  • Alberto Meyer,
  • Wellington Andraus,
  • João Renato Rebello Pinho,
  • Eduardo Guimarães Hourneaux de Moura,
  • João Carlos Setubal,
  • Luiz Augusto Carneiro-D'Albuquerque

DOI
https://doi.org/10.1371/journal.pone.0242553
Journal volume & issue
Vol. 15, no. 11
p. e0242553

Abstract

Read online

BackgroundThe performance of the microbiota is observed in several digestive tract diseases. Therefore, reaching the biliary microbiota may suggest ways for studies of biomarkers, diagnoses, tests and therapies in hepatobiliopancreatic diseases.MethodsBile samples will be collected in endoscopic retrograde cholangiopancreatography patients (case group) and living liver transplantation donors (control group). We will characterize the microbiome based on two types of sequence data: the V3/V4 regions of the 16S ribosomal RNA (rRNA) gene and total shotgun DNA. For 16S sequencing data a standard 16S processing pipeline based on the Amplicon Sequence Variant concept and the qiime2 software package will be employed; for shotgun data, for each sample we will assemble the reads and obtain and analyze metagenome-assembled genomes.ResultsThe primary expected results of the study is to characterize the specific composition of the biliary microbiota in situations of disease and health. In addition, it seeks to demonstrate the existence of changes in the case of illness and also possible disease biomarkers, diagnosis, interventions and therapies in hepatobiliopancreatic diseases.Trial registrationNCT04391426. Registered 18 May 2020, https://clinicaltrials.gov/ct2/show/NCT04391426.